208 related articles for article (PubMed ID: 36581667)
1. Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.
Brum da Silva Nunes V; Kehl Dias C; Nathali Scholl J; Nedel Sant'Ana A; de Fraga Dias A; Granero Farias M; Alegretti AP; Sosnoski M; Esteves Daudt L; Bohns Michalowski M; Oliveira Battastini AM; Paz AA; Figueiró F
Discov Oncol; 2022 Dec; 13(1):143. PubMed ID: 36581667
[TBL] [Abstract][Full Text] [Related]
2. NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia.
da Silva Nunes VB; Dias CK; De Bastiani MA; Farias MG; Spagnol F; Alegretti AP; Daudt LE; Michalowski MB; Battastini AMO; Paz AA; Figueiró F
Purinergic Signal; 2022 Jun; 18(2):211-222. PubMed ID: 35235138
[TBL] [Abstract][Full Text] [Related]
3. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
4. B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.
Zacca ER; Amezcua Vesely MC; Ferrero PV; Acosta CDV; Ponce NE; Bossio SN; Mussano E; Onetti L; Cadile I; Acosta Rodríguez EV; Montes CL; Gruppi A
J Mol Biol; 2021 Jan; 433(1):166687. PubMed ID: 33098857
[TBL] [Abstract][Full Text] [Related]
5. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
6. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
7. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
8. CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease.
Kudryavtsev I; Serebriakova M; Zhiduleva E; Murtazalieva P; Titov V; Malashicheva A; Shishkova A; Semenova D; Irtyuga O; Isakov D; Mitrofanova L; Moiseeva O; Golovkin A
Front Genet; 2019; 10():604. PubMed ID: 31402927
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression.
Kim ES; Ackermann C; Tóth I; Dierks P; Eberhard JM; Wroblewski R; Scherg F; Geyer M; Schmidt RE; Beisel C; Bockhorn M; Haag F; van Lunzen J; Schulze Zur Wiesch J
J Leukoc Biol; 2017 May; 101(5):1263-1271. PubMed ID: 28193736
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional characteristics of CD39
Figueiró F; Muller L; Funk S; Jackson EK; Battastini AM; Whiteside TL
Oncoimmunology; 2016 Feb; 5(2):e1082703. PubMed ID: 27057473
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
12. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.
Gardani CFF; Pedrazza EL; Paz VS; Zanirati GG; da Costa JC; Andrejew R; Ulrich H; Scholl JN; Figueiró F; Rockenbach L; Morrone FB
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004484
[TBL] [Abstract][Full Text] [Related]
13. [Detection and Analysis of T Lymphocyte Subsets and B Lymphocytes in Patients with Acute Leukemia].
Cheng J; Ma HZ; Zhang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):327-330. PubMed ID: 30998133
[TBL] [Abstract][Full Text] [Related]
14. Adenosine production by human B cells and B cell-mediated suppression of activated T cells.
Saze Z; Schuler PJ; Hong CS; Cheng D; Jackson EK; Whiteside TL
Blood; 2013 Jul; 122(1):9-18. PubMed ID: 23678003
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
16. The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation.
Roberts V; Stagg J; Dwyer KM
Front Immunol; 2014; 5():64. PubMed ID: 24600452
[TBL] [Abstract][Full Text] [Related]
17. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
Pietrobon AJ; Andrejew R; Custódio RWA; Oliveira LM; Scholl JN; Teixeira FME; de Brito CA; Glaser T; Kazmierski J; Goffinet C; Turdo AC; Yendo T; Aoki V; Figueiró F; Battastini AM; Ulrich H; Benard G; Duarte AJDS; Sato MN
Front Immunol; 2022; 13():1012027. PubMed ID: 36248842
[TBL] [Abstract][Full Text] [Related]
18. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
Zhu Y; Zhuang Z; Wu Q; Lin S; Zhao N; Zhang Q; Xie L; Yu S
Am J Chin Med; 2021; 49(3):661-676. PubMed ID: 33683190
[TBL] [Abstract][Full Text] [Related]
19. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
20. Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression.
Kolbe K; Wittner M; Hartjen P; Hüfner AD; Degen O; Ackermann C; Cords L; Stellbrink HJ; Haag F; Schulze Zur Wiesch J
Front Immunol; 2022; 13():867167. PubMed ID: 35529864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
